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Introduction
Allogeneic hematopoietic cell transplantation (HCT) following
reduced-intensity conditioning (RIC) or nonmyeloablative con-
ditioning has been an effective treatment for many patients with
hematological malignancies, as well as for selected patients
with solid cancers or inherited blood disorders.
A number of different RIC or nonmyeloablative conditioning
regimens have been explored. The separation of what consti-
tutes a nonmyeloablative versus a RIC regimen is somewhat
arbitrary (Table 1), although Giralt proposed some criteria for
nonmyeloablative conditioning that included (1) no eradication
of host hematopoiesis, (2) prompt hematologic recovery (o4
weeks) without transplant and (3) presence of mixed chimerism
upon engraftment.1 Similarly, the distinction between RIC and
myeloablative conditioning has been discussed; the criteria
proposed by Giralt1 includedp5 Gy total body irradiation (TBI),
p9 mg/kg busulfan dose, p140 mg/m2 melphalan dose and
p10 mg/kg thiothepa dose.1 RIC regimens have combined
modest doses of fludarabine (used mainly for its immunosup-
pressive activity) with consequent (but nonmyeloablative) doses
of alkylating agents such as melphalan (140 mg/m2)2 or busulfan
(4–8 mg/kg),3 given to produce major anti-tumor effects with the
hope of controlling the malignancy before the occurrence of the
immune-mediated graft-versus-tumor effects. In contrast, non-
myeloablative conditioning has used potent immunosuppressive
regimens to overcome host-versus-graft reactions (graft rejec-
tion),4,5 allowing engraftment of donor hematopoietic and
immune cells. Thus, following nonmyeloablative conditioning,
eradication of both host hematopoiesis and tumor cells is
mediated nearly exclusively by immune-mediated graft-versus-
host effects.6,7
The degree of myelosuppression induced by RIC or non-
myeloablative regimens has varied from one regimen to another,
those including intermediate doses of either busulfan (8 mg/kg)
or melphalan (140 mg/m2) being the most myelosuppressive,
whereas the one using low-dose TBI (2 Gy) with or without
fludarabine being the least myelosuppressive (Figure 1 and
Table 1).16
We compared erythropoietic activity in patients given allo-
geneic grafts after either myeloablative (n¼ 57) or nonmyeloa-
blative (n¼ 54) conditioning (Figure 2).17 Nonmyeloablative
conditioning consisted of 2 Gy TBI (n¼ 20), 2 Gy TBI plus
fludarabine (90 mg/m2, n¼ 29), or cyclophosphamide (3 g/m2)
plus fludarabine (90 mg/m2, n¼ 5). Erythropoietic activity was
quantified by assessing the levels of the serum soluble transferrin
receptor (sTfR, a quantitative marker of total erythropoietic
activity). After myeloablative conditioning, erythropoietic
activity decreased sharply and remained abnormally low the
first month after HCT. In contrast, erythropoietic activity
remained consistently above the lower limit of normal values
after nonmyeloablative conditioning, demonstrating that the
regimens were indeed mildly myelosuppressive.
In this article, we first describe what is currently known about
red blood cell (RBC) and platelet transfusion requirements after
RIC or nonmyeloablative conditioning, and then review which
factors are associated with increased transfusion requirements.
In the second part of the review, we discuss the potential role of
hematopoietic growth factors such as erythropoietin (Epo) or
granulocyte colony-stimulating factor (G-CSF) after nonmyelo-
ablative or RIC HCT.
RBC transfusions
RBC transfusion requirements
Given that some degree of erythropoietic activity persists
after nonmyeloablative conditioning,17 it was expected that
patients receiving nonmyeloablative conditioning would require
less RBC transfusions than those given myeloablative regimens.
Indeed, several studies found decreased RBC transfusion require-
ments after nonmyeloablative conditioning or RIC in comparison
to what is seen after myeloablative conditioning.18–20
Weissinger et al.18 compared RBC transfusions in patients
given allogeneic peripheral blood stem cells (PBSC) from human
leukocyte antigen (HLA)-identical siblings after nonmyeloabla-
tive (n¼ 40) versus myeloablative (n¼ 67) conditioning. Non-
myeloablative conditioning consisted of 2 Gy TBI with (n¼ 10)
or without (n¼ 30) added fludarabine (90 mg/m2). Sixty-three
percent of the nonmyeloablative recipients required RBC
transfusions compared to 96% of those given myeloablative
conditioning (P¼ 0.0001). Furthermore, the number of RBC
units transfused was reduced in nonmyeloablative recipients
with a median of 2 (range, 0–50) units transfused versus 6
(range, 0–34) in those receiving myeloablative conditioning
(P¼ 0.0001). High transfusion requirements before HCT
(P¼ 0.0005) and donor–recipient ABO incompatibility (major
mismatch, P¼ 0.0001) were each associated with increased
RBC transfusion requirements in both patient groups. Similar
findings were found by Sorror et al.19 comparing data from
patients given HLA-matched unrelated grafts after nonmyelo-
ablative (consisting of 2 Gy TBI plus fludarabine, n¼ 60) versus
myeloablative conditioning (n¼ 74). Specifically, 88% of
nonmyeloablative recipients received a median of three RBC
transfusions compared to 100% myeloablative recipients, who
required a median of five RBC transfusions (P¼ 0.005).
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Ivanov et al.20 analyzed RBC transfusion requirements in 110
consecutive patients given grafts from HLA-identical siblings
after RIC (n¼ 64; consisting of fludarabine 180 mg/m2, oral
busulfan 8 mg/kg and various doses of anti-thymocyte globulins
(ATG)) or myeloablative conditioning (n¼ 46). Postgrafting
immunosuppression included cyclosporine (CSP) given alone
in all RIC recipients and in 18 of 46 myeloablative recipients,
or combined with short methotrexate (MTX) in 28 myelo-
ablative recipients. Eighty-nine percent of the patients given RIC
required RBC transfusions compared to 100% of myelo-
ablative recipients. In addition, the number of RBC units
transfused was significantly reduced in RIC recipients, with a
median of 4 (range, 0–28) units transfused versus 12 (range,
2–56) in those given myeloablative conditioning (Po0.0001). In
multivariate analysis, high RBC transfusion requirements were
independently predicted by myeloablative conditioning versus
RIC (P¼ 0.0005), and marrow versus PBSC as stem cell source
(Po0.0001). Further, among RIC recipients, low hemoglobin
(Hb) levels before HCT (Po0.0001) and high ATG doses
(P¼ 0.009) were each independently associated with high
RBC transfusion requirements.
Le Blanc et al.21 analyzed data from 58 patients given
grafts after nonmyeloablative conditioning (n¼ 24; consisting of
fludarabine plus 2 Gy TBI) versus RIC (n¼ 34; consisting mainly
of fludarabine 180 mg/m2, oral busulfan 8 mg/kg and ATG)
conditioning. Postgrafting immunosuppression combined CSP
with either mycophenolate mofetil (MMF) or MTX. The number
of RBC units transfused was significantly reduced in nonmye-
loablative recipients, with a median of 0 (range, 0–12) units
transfused versus 4 (range, 0–23) in those given RIC (P¼ 0.02).
Finally, Canals et al.22 studied data from 77 patients given
PBSC after RIC consisting of fludarabine (150 mg/m2) plus either
melphalan (140 mg/m2) or busulfan (10 mg/kg). Postgrafting
immunosuppression combined CSP and short MTX. The main
factor increasing RBC transfusion requirements was the occur-
rence of severe acute graft-versus-host disease (GVHD).
Specifically, patients with grade III–IV acute GVHD (n¼ 12)
required a median of 15 (range, 8–40) RBC units the first 100
days after HCT, whereas patients without grade III–IV acute
GVHD (n¼ 65) received a median of 2 (range, 0–14) RBC units
(Po0.01). In patients without grade III–IV acute GVHD, RBC
transfusion requirements until day 100 after HCT were higher in
patients with major ABO mismatch than in those given ABO-
compatible grafts (P¼ 0.02).
Taken together, these studies suggested that intensity of the
conditioning regimen, Hb levels before HCT, stem cell source,
acute GVHD and major ABO mismatch affected RBC transfu-
sion requirements after nonmyeloablative or RIC HCT (Table 2).
The case of ABO incompatibility
ABO antigens are potent immunogens expressed on the surface
of RBC, RBC progenitors/precursors and also on the surface of a
number of nonhematopoietic cells. Although the ABO group
Figure 1 Neutrophil, Hb and platelet count changes after HLA-
matched related (n¼85) or unrelated (n¼35) HCT following
conditioning with 2 Gy TBI with or without fludarabine (90 mg/m2)
(n¼ 120).25 The graph shows the medians (black squares), 25th
percentile (open triangles) and 75th percentile (inverted open
triangles). Neutrophil counts stayed above 500/ml and platelet counts
remained above 40 000/ml in the majority of patients, demonstrating
that the conditioning is truly nonmyeloablative. This figure was
originally published in Blood (Baron et al. Kinetics of engraftment
in patients with hematologic malignancies given allogeneic HCT
after nonmyeloablative conditioning. Blood 104: 2254–2262).
&The American Society of Hematology.
Table 1 Commonly used nonmyeloablative or RIC regimens in
relation to their myelosuppressive properties8
Regimen (reference)
Nonmyeloablative
Low-dose TBI (2 Gy)5,9





Fludarabine+oral busulfan (8 mg/kg)+ATG3,14,15
Abbreviations: ATG, anti-thymocyte globulin; RIC, reduced-intensity
conditioning; TBI, total body irradiation. [2]Regimens are classified from
less to more myelosuppressive. Note that this classification is not
based on direct experimentation, and is thus hypothetical.
Criteria for RIC includedp5 Gy TBI,p9 mg/kg busulfan,p140 mg/m2
melphalan and p10 mg/kg thiothepa.1
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system has been of critical importance in transfusion medicine,
it has had little impact on HCT outcomes after myeloablative
conditioning.23 Indeed, although the presence of a major ABO
mismatch between donor and recipient was associated with
delayed recovery of erythropoietic activity and occurrence of
pure red cell aplasia, it did not have any impact on the
incidence of grade II–IV acute GVHD or on overall survival.23
The mechanisms of erythropoietic impairment in case of ABO
mismatch after myeloablative conditioning have not been
completely elucidated, but include direct inhibition of donor
erythropoiesis by residual host-derived anti-ABO isohemagglu-
tinins (HA),24 even if virtually all host-derived hematopoiesis
(including plasma cells producing anti-donor HA) has been
eradicated by the conditioning regimen.
As an important characteristic of many nonmyeloablative
regimens has been the persistence of a certain amount of host-
derived hematopoiesis (including B-cell lymphopoiesis) for up
to 6–12 months after HCT,4,6,25 it has been hypothesized that
delayed disappearance of host plasma cells producing anti-
donor HA might lead to particularly delayed donor erythro-
poiesis, and a high frequency of pure red cell aplasia, after
ABO-incompatible nonmyeloablative HCT.
Supporting this hypothesis, Bolan et al.26 found that donor
RBC chimerism (defined as the initial detection of donor RBCs in
peripheral blood) was markedly delayed following nonmyelo-
ablative (n¼ 14) versus myeloablative (n¼ 12) conditioning
(median, 114 versus 40 days; Po0.0001) in patients with major
ABO incompatibility with their donor. Further, four out of 14
nonmyeloablative versus zero out of 12 myeloablative reci-
pients experienced pure red cell aplasia (P¼ 0.10). Interestingly,
donor RBC chimerism closely correlated with decreasing host
anti-donor HA levels. The latter disappeared more slowly
after nonmyeloablative than after myeloablative conditioning
(median, 83 versus 44 days; P¼ 0.03). In addition, CSP disconti-
nuation induced potent graft-versus-plasma cell effects, and
allowed resolution of pure red cell aplasia in all four patients.
The existence of a graft-versus-plasma cell effect was further
supported by the observation that severe acute GVHD was
associated with a rapid decrease in anti-donor HA titers in two
patients, in agreement with a previous study by Mielcarek
et al.27 showing faster decrease in anti-donor HA in patients
developing acute GVHD than in those without acute GVHD,
after myeloablative conditioning. However, a recent study
described the persistence of significant percentages of recipient-
derived plasma cells in patients with pure red cell aplasia after
nonmyeloablative conditioning, despite full donor T-cell and
granulocyte chimerisms.28 This suggests that host-derived
plasma cells might be less susceptible than host-derived T cells
or myeloid cells to donor-derived alloreactive T cells.29
In agreement with the study of Bolan et al.,26 Zaucha et al.30
found that the median time to reach HA titerso1:1 was at least
133 days in patients given ABO-incompatible grafts after
nonmyeloablative conditioning, approximately twice longer
than after myeloablative conditioning. Further, donor erythro-
poiesis was effective only when low or absent anti-donor HA
titers were achieved.
Finally, it should be emphasized that some RIC regimens,
particularly those containing alemtuzumab, are likely to
eradicate most of the host-derived anti-donor HA-producing
plasma cells, and thus might not be associated with delayed
donor RBC chimerism in comparison to what is seen with
myeloablative conditioning.31
Platelet transfusions
Several studies have found lower platelet transfusion require-
ments in patients given nonmyeloablative conditioning or RIC
than in those receiving a myeloablative regimen.18,19
Weissinger et al.18 studied platelet transfusion requirements in
patients given allogeneic PBSC from HLA-identical siblings after
nonmyeloablative (n¼ 40) versus myeloablative (n¼ 67) con-
ditioning. Nonmyeloablative conditioning consisted of 2 Gy TBI
with (n¼ 10) or without (n¼ 30) added fludarabine (90 mg/m2).
Twenty-three percent of nonmyeloablative recipients required
platelet transfusions compared to 100% of those given
myeloablative conditioning (Po0.0001). Further, the number
of platelet units given was reduced after nonmyeloablative
conditioning, with a median of 0 (range, 0–214) units transfused
versus 24 (range, 4–358) after myeloablative conditioning
(Po0.0001). High platelet transfusion requirements before
HCT were also associated with increased transfusion require-
ments in both patient groups (P¼ 0.01).
Sorror et al.19 analyzed transplantation-related toxicities
including transfusion requirements after HLA-matched unrelated
HCT in 134 concurrent patients given either nonmyeloablative
(n¼ 60) or myeloablative (n¼ 74) conditioning. Sixty-three
percent of nonmyeloablative patients received a median of
Table 2 Factors associated with high transfusion requirements after
nonmyeloablative or RIC HCT
Factor Transfusions (reference)
RBC Platelets
Poor marrow function before HCTa Yes18,20 Yes18
Intensity of the conditioning regimen Yes18–21 Yes18,19,21
Stem cell source Yes20 Not known
Major ABO mismatch Yes18,22 Not known
Severe acute GVHD Yes22 Yes22
Abbreviations: GVHD, graft-versus-host disease; HCT, hematopoietic
cell transplantation; RBC, red blood cell; RIC, reduced-intensity
conditioning.
aAssessed by hemoglobin values and/or pre-HCT RBC transfusion
requirements for RBC transfusions, or by platelet levels and/or
pre-HCT platelet transfusion requirements for platelet transfusions.
Figure 2 Erythropoietic activity, as assessed by sTfR levels
(mean7s.e.m.) after nonmyeloablative (PBSC, n¼ 54) HCT versus
myeloablative (marrow (BMT, n¼47) or PBSC (PBSCT, n¼10)) HCT.
Horizontal lines show the upper and lower limits of normal values.
P-values are given for comparisons between the nonmyeloablative
PBSC and the myeloablative PBSC groups: *Po0.05, **Po0.01,
***Po0.001.
Transfusions after RIC











one platelet transfusion compared to all myeloablative patients
given a median of seven transfusions (Po0.0001).
Le Blanc et al.21 compared platelet transfusion requirements
in 58 patients given grafts after nonmyeloablative (n¼ 24;
consisting of fludarabine plus 2 Gy TBI) versus RIC (n¼ 34;
consisting mainly of fludarabine 180 mg/m2, oral busulfan 8 mg/
kg and ATG) conditioning. Postgrafting immunosuppression
combined CSP with either MMF or MTX. The number of platelet
units transfused was significantly reduced in nonmyeloablative
recipients with a median of 0 (range, 0–6) units transfused versus
2 (range, 0–24) in those given RIC (Po0.001).
Canals et al.22 studied data from 77 patients given PBSC after
RIC consisting of fludarabine (150 mg/m2) plus either melphalan
(140 mg/m2) or busulfan (10 mg/kg). Postgrafting immunosup-
pression combined CSP and short MTX. As observed for RBC
transfusion requirements, the main factor increasing platelet
transfusion requirements was the occurrence of severe acute
GVHD. Specifically, patients with grade III–IV acute GVHD
(n¼ 12) required a median of 15 (range, 4–20) platelet
transfusions the first 100 days after HCT, whereas patients
without grade III–IV acute GVHD (n¼ 65) received a median of
2 (range, 0–20) platelet transfusions (Po0.01).
Finally, Mohty et al. analyzed platelet recovery and trans-
fusion needs in 90 patients receiving grafts from HLA-identical
siblings after a RIC regimen consisting mainly of fludarabine,
busulfan and ATG (Mohty M et al. Blood 2005; 106 (Part 1):
abstract #961). Low platelet counts before RIC (P¼ 0.07)
and occurrence of grade III–IV acute GVHD (P¼ 0.0001)
were associated with increased requirements for platelet
transfusions.
Potential role for hematopoietic growth factors
Epo
Epo is the key regulatory factor of erythropoiesis, and acts
mainly by preventing apoptosis of late erythroid progenitors. In
normal patients, serum Epo levels increase exponentially with
decreasing Hb levels. After myeloablative allogeneic HCT,
serum Epo levels first rapidly increased to disproportionately
high levels for 1–3 weeks and then became inappropriately low
for the degree of anemia, resulting in low erythropoietic activity
and prolonged anemia.32 As predicted by these observations,
Epo therapy offered minimal benefit when started immediately
after HCT,33 but was quite efficient when started more than
4 weeks after HCT,34 that is, when serum Epo production
became impaired.
There are two important differences in the physiology of
erythropoiesis following nonmyeloablative versus myeloablative
conditioning. First, a certain amount of host erythropoietic
activity persists after nonmyeloablative conditioning (Figure 2),
suggesting that Epo therapy might be efficient even when started
on day 0 after nonmyeloablative HCT. Secondly, contrary to
endogeneous Epo deficiency observed after myeloablative
Figure 3 Hb values and sTfR levels after nonmyeloablative HCT in patients given (n¼46) or not given (control group, n¼ 14) rHuEpo. Values are
normalized relative to their value on the day of transplantation. The right panels provide the evolution in Epo group 1 (rHuEpo started on day 0;
n¼19) and left panels the evolution in Epo group 2 (rHuEpo started on day 30; n¼27). P-values are given for comparisons with the control group
at any particular time point by Student’s t-tests (*o0.05,**o0.01, ***o0.001). Reproduced with permission from Vanstraelen et al.36
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conditioning, Epo production remains adequate for the degree
of anemia throughout the post-transplant period after non-
myeloablative conditioning, suggesting that Epo therapy might
be less efficient after nonmyeloablative than after myelo-
ablative conditioning, when started after 4 weeks following
transplantation.17
Two recent studies have investigated the use of Epo after
nonmyeloablative conditioning or RIC.35,36 Ivanov et al.35 gave
Epo (either 30 000 IU epoetin-beta or 150 mg darbepoetine-
alpha per week, started on day 1) to 20 consecutive patients
following RIC allogeneic HCT (Epo group). Conditioning
combined fludarabine, busulfan and ATG. Epo therapy was
continued until the Hb level reached 14 g/dl or until day 60.
Twenty-seven matched patients not receiving recombinant
human erythropoietin (rHuEpo) served as controls (control
group). Median Hb levels on days 30 and 60 after HCT were
11.6 and 12.8 g/dl in the Epo group versus 10.0 g/dl (P¼ 0.0001)
and 9.9 g/dl (Po0.0001) in the control group, respectively. In
addition, there was a trend for lower RBC transfusion require-
ments in the Epo group (median 2 units (range, 2–4 units))
compared to the control group (median 4 units (range, 2–12
units); P¼ 0.07).
We analyzed erythropoietic activity (assessed by sTfR levels)
and Hb levels in 60 patients given allogeneic grafts after
nonmyeloablative conditioning.36 Fourteen patients did not
receive Epo (control group), 19 were given Epo from day 0 after
HCT (Epo group 1), whereas 27 were scheduled to start Epo on
day 28 after HCT (Epo group 2). Recombinant human Epo was
administered subcutaneously at a dose of 500 U/kg/week, with
the aim of achieving Hb levels of 13 g/dl. During the first month
as well as between days 30 and 180, sTfr levels and Hb values
were significantly higher in patients receiving rHuEpo compared
to those not receiving it (Figure 3). However, transfusion
requirements were significantly decreased only during the first
month in patients given Epo from day 0 (Epo group 1,
P¼ 0.0169). Interestingly, donor T-cell chimerism levels above
60% on day 42 was the best predictor of achieving Hb values
413 g/dl, suggesting possible inhibition of donor erythropoiesis
by residual recipient lymphocytes, in patients with low donor
T-cell chimerism levels.
Taken together, these studies indicated that giving Epo (either
30 000 IU epoetin or 150 mg darbepoetin-alpha per week) early
after nonmyeloablative or RIC HCT could reduce RBC trans-
fusion needs. A prospective randomized trial is ongoing at our
center, with Epo starting around day 0, to assess its clinical
benefit in terms of transfusion requirements and quality of life.
However, until the clinical benefits of Epo therapy in this setting
are clearly demonstrated, its use should be restricted to patients
included in clinical trials.
G-CSF
G-CSf has been administered to hasten neutrophil recovery after
myeloablative allogeneic HCT, and its potential impact on
immune recovery and GVHD incidence has been extensively
debated (reviewed by Mohty et al.37). However, no study thus
far analyzed the impact of G-CSF use after nonmyeloablative
conditioning or RIC. Some groups of investigators gave G-CSF in
most patients,2,38 whereas others either did not use it or gave it
only in case of granulocytopenia.5,39,10 In one study, in which
RIC consisted of fludarabine (150 mg/m2), melphalan (140 mg/
m2) and alemtuzumab (100 mg) and postgrafting immunosup-
pression of CSP alone, there was a suggestion that time
to neutrophil recovery could be 1 day shorter in patients given
G-CSF at 5 mg/kg/day (1373 days, n¼ 32) compared to those
not given G-CSF (1474 days, n¼ 6) (NS). Prospective rando-
mized studies are therefore needed to clarify the impact of
G-CSF administration on HCT outcome after nonmyeloablative
or RIC regimens.
Conclusion
Despite the fact that nonmyeloablative and RIC regimens are
associated with lower transfusion requirements than myelo-
ablative ones, most patients given nonmyeloablative condition-
ing or RIC required RBC and/or platelet transfusions. Predictive
factors for high transfusion requirements include low Hb or
platelet values before HCT, intensity of the conditioning
regimen, use of marrow instead of PBSC as stem cell source,
occurrence of severe acute GVHD and major ABO mismatch
(for RBC transfusions). In case of major ABO incompatibility,
donor erythroid engraftment is further delayed after nonmyelo-
ablative compared to myeloablative conditioning, because of
the persistence of anti-donor HA-secreting host-derived plasma
cells for up to several months after nonmyeloablative condition-
ing. The potential role of hematopoietic growth factors such as
Epo, G-CSF, thrombopoietin or thrombopoietin receptor ligands
(such as the AMG 531, which has shown promising activity in
patients with immune thrombocytopenic purpura)40 warrants
further investigations. Their rational use might allow performing
nonmyeloablative or RIC HCT without RBC and platelet
transfusions in most patients.
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